JAMA Dermatology

<jats:sec id="ab-doi250017-4"><jats:title>Importance</jats:title><jats:p>Skin cancer is a significant public health threat in the aging population, yet data on its burden and trends are limited.</jats:p></jats:sec><jats:sec id="ab-doi250017-5"><jats:title>Objective</jats:title><jats:p>To evaluate the global burden of skin cancer among adults 65 years or older from 1990 to 2021, and to project its change to 2050.</jats:p></jats:sec><jats:sec id="ab-doi250017-6"><jats:title>Design, Setting, and Participants</jats:title><jats:p>In this observational study, population-based registry data were extracted from the Global Burden of Diseases (GBD) Study 2021. The database covers 204 countries and territories, ensuring global applicability of the results. Data analysis was conducted from June 9, 2024, to February 18, 2025.</jats:p></jats:sec><jats:sec id="ab-doi250017-7"><jats:title>Main Outcomes and Measures</jats:title><jats:p>Age-standardized rates of prevalence, incidence, deaths, and disability-adjusted life-years (DALYs) were calculated per 100 000 population. Estimated rates of disease burden were calculated for 2050.</jats:p></jats:sec><jats:sec id="ab-doi250017-8"><jats:title>Results</jats:title><jats:p>A worldwide total of 153 993 melanoma, 1 463 424 squamous cell carcinoma (SCC), and 2 802 354 basal cell carcinoma (BCC) instances were estimated for 2021. SCC exhibited the highest age-standardized rate of prevalence (236.91 per 100 000 population; 95% uncertainty interval [UI], 188.23-303.82), deaths (6.16 per 100 000 population; 95% UI, 5.13-6.87), and DALYs (95.50 per 100 000 population; 95% UI, 81.65-106.39), whereas BCC displayed the highest incidence rate (371.97 per 100 000 population; 95% UI, 310.75-439.58). The disease burden was notably greater in male individuals than in female individuals. During the observation period, the global burden of skin cancer among older people demonstrated a general upward trend. Decomposition analysis indicated that population growth was the primary contributor to this increase. Health-inequality analysis revealed a disproportionately higher burden shouldered by countries with higher sociodemographic index (SDI) levels. Frontier analysis identified the countries with considerable potential to mitigate skin cancer. It was anticipated that only incidence and prevalence rates attributable to keratinocyte cancer (KC), along with DALYs rate related to BCC, would increase by 2050.</jats:p></jats:sec><jats:sec id="ab-doi250017-9"><jats:title>Conclusions and Relevance</jats:title><jats:p>The older population (particularly male individuals and those living in high-SDI countries) is facing a substantial growing burden of skin cancer. Despite the relative incompleteness of KC data and lack of race and ethnicity data, these results highlight the urgency for more effective prevention and management strategies targeting high-risk groups.</jats:p></jats:sec>

The global burden of skin cancer: a longitudinal analysis from the Global Burden of Disease Study, 1990-2017.

JAAD Int

United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019.

J Am Acad Dermatol

Financial worry in people with cancer: relationship to employment and outcomes.

Psychooncology

Effect of age on melanoma risk, prognosis and treatment response.

Acta Derm Venereol

Aging trends in skin cancer: a long-term observational study in Japan.

Skin cancer epidemics in the elderly as an emerging issue in geriatric oncology.

Aging Dis

Melanoma incidence increases in the elderly of Catalonia but not in the younger population: effect of prevention or consequence of immigration?

Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.

Lancet

Global burden of non-communicable diseases attributable to kidney dysfunction with projection into 2040.

Chin Med J (Engl)

The global burden of scabies: a cross-sectional analysis from the Global Burden of Disease Study 2015.

Lancet Infect Dis

Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017.

Inj Prev

Global, regional, and national burden of inguinal, femoral, and abdominal hernias: a systematic analysis of prevalence, incidence, deaths, and DALYs with projections to 2030.

Int J Surg

Global, regional, and national burden of CKD due to glomerulonephritis from 1990 to 2019: a systematic analysis from the Global Burden of Disease Study 2019.

Clin J Am Soc Nephrol

Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10-24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019.

Lancet Child Adolesc Health

Global, regional, and national burden of preterm birth, 1990-2021: a systematic analysis from the global burden of disease study 2021.

EClinicalMedicine

The global, regional, and national patterns of change in the burden of congenital birth defects, 1990-2021: an analysis of the global burden of disease study 2021 and forecast to 2040.

Global, regional, and national burden of cancers attributable to particulate matter pollution from 1990 to 2019 and projection to 2050: Worsening or improving?

J Hazard Mater

Revisiting Das Gupta: refinement and extension of standardization and decomposition.

Demography

Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study.

JAMA Oncol

Promoting health equity: WHO health inequality monitoring at global and national levels.

Glob Health Action

The health equity measurement framework: a comprehensive model to measure social inequities in health.

Int J Equity Health

The global, regional, and national patterns of change in the burden of nonmalignant upper gastrointestinal diseases from 1990 to 2019 and the forecast for the next decade.

Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019.

Autoimmun Rev

Rheumatic heart disease burden, trends, and inequalities in the Americas, 1990-2017: a population-based study.

Lancet Glob Health

Calculating concentration index with repetitive values of indicators of economic welfare.

J Health Econ

Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016.

Kidney Int

Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study.

Biomark Res

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.

Spatiotemporal trends of the global burden of melanoma in 204 countries and territories from 1990 to 2019: Results from the 2019 global burden of disease study.

Neoplasia

Trends in keratinocyte skin cancer incidence, mortality and burden of disease in 33 countries between 1990 and 2017.

Br J Dermatol

Clinical implications of aging skin: cutaneous disorders in the elderly.

Am J Clin Dermatol

Sun protective behaviors among US racial and ethnic minorities with sun-sensitive skin.

Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches.

Dermatol Ther (Heidelb)

Age-specific incidence of melanoma in the United States.

JAMA Dermatol

Cancer registration in China and its role in cancer prevention and control.

Lancet Oncol

Non-melanoma skin cancers in the older patient.

Curr Oncol Rep

Skin cancers and their risk factors in older persons: a population-based study.

BMC Geriatr

Analysis of prevalence, socioeconomic and disease trends of non-melanoma skin cancer in New Zealand from 2008 to 2022.

J Epidemiol Glob Health

Sex-based differences in melanoma survival improvement from 2004 to 2018.

Cancers (Basel)

Let’s talk about sex: a biological variable in immune response against melanoma.

Pigment Cell Melanoma Res

Estimated healthcare costs of melanoma and keratinocyte skin cancers in Australia and Aotearoa New Zealand in 2021.

Int J Environ Res Public Health

Sunburn, sunbeds and melanoma skin cancer: a story behind the statistics.

Clin Exp Dermatol

Basal cell carcinoma, squamous cell carcinoma and melanoma of the skin: analysis of the Singapore Cancer Registry data 1968-97.

Systemic therapy of metastatic melanoma: on the road to cure.

Oncology (Williston Park)

Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.

Front Immunol

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.

Eur J Cancer

Mortality from nonmelanoma skin cancer in Australia from 1971 to 2021.

Development of a healthy ageing index in Latin American countries - a 10/66 dementia research group population-based study.

BMC Med Res Methodol

Age-related differences in tumour characteristics and prognostic factors for disease progression in cutaneous squamous cell carcinoma of the head and neck.

Systematic skin examination in an acute geriatric unit: skin cancer prevalence.

Skin cancer is a significant public health threat in the aging population, yet data on its burden and trends are limited.
To evaluate the global burden of skin cancer among adults 65 years or older from 1990 to 2021, and to project its change to 2050.
In this observational study, population-based registry data were extracted from the Global Burden of Diseases (GBD) Study 2021. The database covers 204 countries and territories, ensuring global applicability of the results. Data analysis was conducted from June 9, 2024, to February 18, 2025.
Age-standardized rates of prevalence, incidence, deaths, and disability-adjusted life-years (DALYs) were calculated per 100 000 population. Estimated rates of disease burden were calculated for 2050.
A worldwide total of 153 993 melanoma, 1 463 424 squamous cell carcinoma (SCC), and 2 802 354 basal cell carcinoma (BCC) instances were estimated for 2021. SCC exhibited the highest age-standardized rate of prevalence (236.91 per 100 000 population; 95% uncertainty interval [UI], 188.23-303.82), deaths (6.16 per 100 000 population; 95% UI, 5.13-6.87), and DALYs (95.50 per 100 000 population; 95% UI, 81.65-106.39), whereas BCC displayed the highest incidence rate (371.97 per 100 000 population; 95% UI, 310.75-439.58). The disease burden was notably greater in male individuals than in female individuals. During the observation period, the global burden of skin cancer among older people demonstrated a general upward trend. Decomposition analysis indicated that population growth was the primary contributor to this increase. Health-inequality analysis revealed a disproportionately higher burden shouldered by countries with higher sociodemographic index (SDI) levels. Frontier analysis identified the countries with considerable potential to mitigate skin cancer. It was anticipated that only incidence and prevalence rates attributable to keratinocyte cancer (KC), along with DALYs rate related to BCC, would increase by 2050.
The older population (particularly male individuals and those living in high-SDI countries) is facing a substantial growing burden of skin cancer. Despite the relative incompleteness of KC data and lack of race and ethnicity data, these results highlight the urgency for more effective prevention and management strategies targeting high-risk groups.

Burden of Skin Cancer in Older Adults From 1990 to 2021 and Modelled Projection to 2050.

Burden of Skin Cancer in Older Adults From 1990 to 2021 and Modelled Projection to 2050

Burden of Skin Cancer in Older Adults From 1990 to 2021 and Modelled Projection to 2050

Clinical Summary

What was studied

Key findings

Study limitations

Clinical implications

Related Questions